Chief Scientific Officer
Michael Agrez MBBS MS PhD FRCS FRACS
Michael’s career background is a combination of basic science research and clinical practice as a colorectal surgeon since working at the Mayo Clinic in 1980. During his 30-year tenure with The University of Newcastle, Australia, he has published numerous articles in peer-reviewed journals that cover aspects of epidemiology, cancer screening, molecular biology, biochemistry and immunology. During the past 10 years InterK has developed immuno-modulating peptides that have potential to inhibit cancer growth, autoimmune responses, endometriosis and repair radiation-induced DNA damage.
A/g CEO
Stephen Parker, Business Operations
Stephen has been involved with all aspects of new product development and commercialisation in the biotech sector for the last thirty five years. Prior to his involvement with InterK Stephen patented and subsequently successfully commercialized a range of surgical devices.
Share this page